The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

The BC Cancer Foundation is launching a fundraising campaign to support the next three years of immunotherapy research at BC ...

Diffuse midline gliomas (DMGs) are some of the most aggressive and deadly childhood brain tumors. These cancers, which mainly ...

A team led by the Institute for Bioengineering of Catalonia (IBEC) and the Hospital del Mar Research Institute has developed ...

This approach aims to improve treatment for patients with this highly aggressive and treatment-resistant type of breast ...

BofA has initiated coverage of Candel Therapeutics (NASDAQ:CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. "While approved therapies may have ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.